Tick-borne pathogens such as Borrelia, Babesia, and Bartonella often go undetected due to low abundance and immune evasion. Galaxy’s multi-layered testing strategy helps detect what others miss.
Because these infections behave unpredictably, circulating one day and hiding the next, single-point testing often misses them. Their shifting presence in blood and tissues means that even well-designed panels can fail to detect current presence of a pathogen. That’s why many clinicians find traditional testing can’t keep pace with what’s happening inside the patient.
Stealth pathogens demand a smarter diagnostic strategy, one that looks beyond antibodies and timing.
Galaxy’s suspected tick-borne illness testing integrates multiple diagnostic perspectives to give clinicians a clearer picture of infection status. Each layer contributes unique insight. Together, they improve diagnostic confidence.
Testing across three days helps capture pathogens that circulate intermittently in the bloodstream.
Not all days yield the same results, serial draws matter.
By measuring antibody levels against Bartonella, this test helps distinguish between past exposure and potential ongoing infection, supporting clinical interpretation.
Using Nanotrap® technology, this non-invasive urine test isolates Borrelia OspA antigen directly, providing clarity when antibody-based methods are inconclusive.
